Sinopharm Group is trading at 2.57 as of the 5th of January 2025, a 0.39 percent increase since the beginning of the trading day. The stock's lowest day price was 2.57. Sinopharm Group has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 6th of December 2024 and ending today, the 5th of January 2025. Click here to learn more.
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Sinopharm Group's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Sinopharm Group or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Although Sinopharm Group's alpha and beta are two of the key measurements used to evaluate Sinopharm Group's performance over the market, the standard measures of volatility play an important role as well.
Our tools can tell you how much better you can do entering a position in Sinopharm Group without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Global Correlations Now
Global Correlations
Find global opportunities by holding instruments from different markets
Sinopharm Group financial ratios help investors to determine whether Sinopharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinopharm with respect to the benefits of owning Sinopharm Group security.